Bio-Path (NASDAQ:BPTH – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.02, MarketWatch Earnings reports. During the same quarter last year, the firm earned ($0.49) EPS.
Bio-Path Price Performance
NASDAQ:BPTH traded down $0.01 during mid-day trading on Friday, reaching $0.53. The company’s stock had a trading volume of 66,960 shares, compared to its average volume of 885,266. The stock has a market cap of $6.55 million, a P/E ratio of -0.27 and a beta of 1.11. The company’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.95. Bio-Path has a twelve month low of $0.32 and a twelve month high of $2.35.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in Bio-Path during the third quarter worth approximately $35,000. Virtu Financial LLC purchased a new position in Bio-Path in the 1st quarter worth approximately $38,000. Finally, Renaissance Technologies LLC acquired a new stake in Bio-Path during the 2nd quarter valued at $70,000. 5.74% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
- Five stocks we like better than Bio-Path
- Learn Technical Analysis Skills to Master the Stock Market
- 3 large caps with red hot RSIs with upside
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Johnson Controls International: Nothing but upside for investors
- How Technical Indicators Can Help You Find Oversold Stocks
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.